Karen Walker
Technik-/Wissenschafts-/F&E-Leiter bei KYVERNA THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Karen Walker is currently the Chief Technology Officer at Kyverna Therapeutics, Inc. She is also a member of the Parenteral Drug Association, Alliance For Regenerative Medicine’s Foundation, and PDA ATMP Working Group.
Previously, she held the position of Vice President at Novartis, Inc. and Seagen Inc. Ms. Walker received her undergraduate degree from St. Olaf College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Karen Walker
| Unternehmen | Position | Beginn |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2021 |
| Alliance For Regenerative Medicine’S Foundation | Corporate Officer/Principal | - |
| Parenteral Drug Association | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Karen Walker
| Unternehmen | Position | Ende |
|---|---|---|
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Corporate Officer/Principal | - |
| SEAGEN INC. | Corporate Officer/Principal | - |
Ausbildung von Karen Walker
| St. Olaf College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Novartis, Inc.
Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a company based in San Francisco. | Health Technology |
Seagen Inc.
 Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
| Parenteral Drug Association | |
| Alliance For Regenerative Medicine’S Foundation |
